Early clinical manifestations of Sézary syndrome: A multicenter retrospective cohort study-Reference-Cited by-同舟云学术

Early clinical manifestations of Sézary syndrome: A multicenter retrospective cohort study

Published:2017-10 Issue:4 Volume:77 Page:719-727
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Mangold Aaron R.,Thompson Agnieszka K.,Davis Mark D.,Saulite Ieva,Cozzio Antonio,Guenova Emmanuella,Hodak Emmilia,Amitay-Laish Iris,Pujol Ramon M.,Pittelkow Mark R.,Gniadecki Robert

Publisher

Elsevier BV

Subject

Dermatology

Reference29 articles.

1. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers;Jawed;J Am Acad Dermatol,2014

2. WHO-EORTC classification for cutaneous lymphomas;Willemze;Blood,2005

3. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas;Vonderheid;J Am Acad Dermatol,2002

4. Sézary syndrome: a study of 176 patients at Mayo Clinic;Kubica;J Am Acad Dermatol,2012

5. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions;Jawed;J Am Acad Dermatol,2014

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas;Cancers;2024-09-05

2. Updated cutaneous T-cell lymphoma TNMB staging criteria fail to identify patients with Sézary syndrome with low blood burden;Blood;2024-08-22

3. Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris;Life;2024-07-24

4. Response to Hasan et al’s “Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study”;Journal of the American Academy of Dermatology;2024-07

5. Sezary Syndrome: A Case Report and Review of Current Therapeutics;Cureus;2024-04-18